Surgical clip closure of the left atrial appendage

Fabrizio Rosati MD | Gijs E. de Maat MD, PhD | Mattia A. E. Valente MD | Massimo A. Mariani MD, PhD | Stefano Benussi MD, PhD

1 Division of Cardiac Surgery, Spedali Civili Brescia University Hospital, Brescia, Italy
2 Department of Cardio-thoracic Surgery, University Medical Centre Groningen, Groningen, The Netherlands

Correspondence
Stefano Benussi, MD, PhD, Division of Cardiac Surgery, Spedali Civili Brescia, University of Brescia Medical School, Brescia, Italy, P.le Spedali Civili, 1, 25123 Brescia, Italy. Email: Stefano.benussi@hotmail.it

Abstract
Atrial fibrillation (AF) is the most common atrial arrhythmia, but it is not a benign disease. AF is an important risk factor for thromboembolic events, causing significant morbidity and mortality. The left atrial appendage (LAA) plays an important role in thrombus formation, but the ideal management of the LAA remains a topic of debate. The increasing popularity of surgical epicardial ablation and hybrid endoepicardial ablation approaches, especially in patients with a more advanced diseased substrate, has increased interest in epicardial LAA management. Minimally invasive treatment options for the LAA offer a unique opportunity to close the LAA with a clip device. This review highlights morphologic, electrophysiologic, and surgical aspects of the LAA with regard to AF surgery, and aims to illustrate the importance of surgical clip closure of the LAA.

KEYWORDS
ablation, atrial fibrillation, left atrial appendage

INTRODUCTION
Atrial fibrillation (AF) is the most common atrial arrhythmia. It should not be considered a benign disease, in addition to symptom burden, loss of atrial and potentially ventricular function, AF is an important risk factor for cerebral stoke. This causes significant morbidity and mortality, especially in the aging populations of the developed countries. The left atrial appendage (LAA) plays an important role in thrombus formation. Data suggest that approximately 90% of atrial thrombi in nonrheumatic AF are found within the LAA. Although oral anticoagulants (OACs) offer an important reduction in stroke risk, they also increase bleeding risk.

Benefits of rhythm control for more persistent forms of AF are becoming clearer, but results of catheter ablation remain far from ideal. This led to a growing interest in minimally invasive AF surgery, especially for patients who are refractory to medical and transcatheter therapy.

To date, transcatheter closure of the LAA shows no significant benefit compared to OAC. During thoracoscopic AF ablation, the surgeon has the unique opportunity to manage the LAA. In the past, complete LAA exclusion has proven challenging, while incomplete closure or amputation may increase thrombo-embolic risk. However, clip occlusion devices have simplified surgical LAA management with consistent exclusion and, importantly, electrical isolation of the LAA. Since the introduction of epicardial LAA management, over 250,000 clip occlusions have been performed in patients worldwide. A recent large randomized controlled trial showed a significant reduction in ischemic stroke when LAA amputation or closure was performed as a concomitant procedure, in AF patient undergoing cardiac surgery, demonstrating the potential benefit of appendage...
exclusion. This review highlights morphologic, electrophysiologic, and surgical aspects of the LAA with regard to AF surgery, and aims to illustrate the practical implications for surgical rhythm management.

2 | LAA MANAGEMENT AND EFFECT ON LA AND LV MECHANICAL FUNCTION

Historically considered a useless embryonic remnant, the importance of the LAA is increasingly being recognized. Not merely its role as "the most lethal human attachment" due to its role in cardiac embolisms in AF patients, but also the important role it plays for both LA and LV functions. The LAA can act as a complementary reservoir that refills during left ventricular early systole when the mitral valve is closed and the LA is passively filled. The LAA has been shown to have greater compliance than the LA, particularly in diseases causing volume overload. Therefore, the LAA can play an important role in cardiac pressure-volume regulation. However, decreased LA reservoir function is noted after LAA exclusion without affecting intrinsic LA contractility. During early diastole, the LAA should be considered a compliance chamber that passively fills the LA and LV once the mitral valve is open, while during late diastole, the LAA acts as booster pump due to its intrinsic contractile function, thus contributing to stroke volume. The LAA is calculated to contribute to up to 10% of the total LA volume. However, contemporary series seem to exclude significant echocardiographic variation in LV stroke volume or LVEF in patients in sinus rhythm undergoing LAA occlusion. These data have been confirmed in patients with reduced LVEF (<35%). Despite a global increase in LA reservoir volume, a moderate improvement in conduit and booster pump function may be expected based on the Frank-Starling mechanism. It has to be noted that these findings were from endocardial LAA occlusion; little is known about hemodynamic effects of epicardial LAA occlusion.

3 | LAA MANAGEMENT AND NEUROENDOCRINE EFFECTS

The endocrine role of the LAA is related to the presence of intrinsic stretch-sensitive receptors able to release ANP. Experimental analysis has demonstrated the presence of so-called "ANP densely granulated cells" with the highest concentration in the LAA.
Fluid infusion at the level of the LAA increases blood ANP levels, leading to increased heart rate, natriuresis and diuresis, resulting in reduction of volume load, vasodilatation, and blood pressure decrease. Several studies demonstrated significant downregulation and inhibition of the natriuresis pathway when the LAA is excluded surgically. Furthermore, noradrenaline, adrenaline, renin, and aldosterone are significantly downregulated in patients treated with epicardial LAA exclusion. The appendage is richly innervated by sympathetic and parasympathetic nerves in strict relation to stretch receptors, and interconnected with the angiotensin system activated by ANP release. Turagam et al. demonstrated a significant reduction of systolic and diastolic blood pressure in hypertensive AF patients undergoing epicardial ablation and LAA exclusion, underlining the necessity to reduce antihypertensive medications. Because the original Cox-Maze III operation incorporated excision of the LAA down to its base as well as excision of the right atrial appendage tip, patients developed severe postoperative fluid overload due to the decrease of ANP levels in the blood. Spironolactone should be administered postoperatively to counter this effect. The period of spironolactone administration is at least 1 month in our clinical practice.

4 | LAA MORPHOLOGY

Increased interest in ablation techniques and management of the LAA, combined with improved imaging modalities, have led to classification systems for LAA morphology. The most commonly used Wang classification assigns the LAA to “Cactus,” “Chicken wing,” “Windsock,” or “Cauliflower” (Figure 1) morphologies. Such classifications system may assist both in planning interventions and the identification of “dangerous” appendages that require intervention. Large LAAs and LAAs with single lobe morphology are more frequently present in patients who suffer from stroke. However, AF-induced elevated pressure and subsequently increased LAA volume may alter LAA morphology. The number of LAA lobes is reduced due to the remarkably thin (+/-1 mm) wall, combined with the lack of supporting tissue around the appendage. Additionally, bending of the LAA may occur due to dilatation, creating turbulence and eventually increasing thrombo-embolic risk.

This knowledge may guide patient selection for LAA management, although more studies on this subject are required. For procedural planning, other imaging modalities such as contrast enhanced cardiac computerized tomography (CT) can be utilized, although the static nature of CT means differentiation between thrombus and sluggish flow can be difficult, as images are captured a few seconds after contrast reaches the left heart (LA/LAA). Cardiac magnetic resonance imaging is a promising modality for reliable assessment of LAA shape and dimensions/volume. At times, CCT and CMR can be challenging since irregular heart rate and tachycardia significantly reduce image quality (with an ideal heart rate <65 beats/min). Transesophageal echocardiography (TOE) is used to assess the preprocedural presence of thrombus in the LAA.

5 | THE ROLE OF LAA CLIP OCCLUSION IN THROMBOEMBOLIC STROKE RISK REDUCTION

In general, the LAA is the most common site for cardiac thrombi in patients, both in AF and in SR. LA enlargement promotes stasis and thus thromboembolic risk. An additional stroke risk is the presence of a heavily trabeculated LAA endocardium. Although there is a strong relationship between AF and stroke, the causal relationship between stroke and thrombus formation within the LAA is not undisputed. It has been demonstrated that in AF patient population, 91% of all thrombi were formed within the LAA. In another prospective study, TEE examination show that of 230 patients with AF for >2 days, 33 out of 34 cardiac thrombi were located in the LAA. As a part of the original Cox-Maze procedure, the atrial appendices were routinely amputated, and his group has published extensively on rhythm outcome but also stroke reduction benefit after Maze surgery. The recent LAAOS III trial, randomizing AF patients undergoing cardiac surgery to concomitant LAA closure or not, demonstrated that LAA closure results in a relative stroke risk reduction of 33% at 3.8 years follow-up. Besides stroke risk reduction interventions, patients may present with a thrombus within the LAA. A small case series demonstrated that V-shaped clip can safely exclude partially thrombosed LAAs with minimal manipulation.

6 | THE ROLE OF LAA CLIP OCCLUSION IN RHYTHM CONTROL

Remodeling of the LAA may contribute to the pathogenesis of atrial arrhythmias. Electrical exclusion of the LAA therefore provides an antiarrhythmic benefit. Di Biase et al. reported that 27% of their AF ablation patient population had foci in the LAA, while the LAA was the only mapped trigger in 8.7% of cases. In transcatheter ablations studies in AF, arrhythmia-free survival was better in patients who undergo additional LAA isolation compared to pulmonary vein isolation alone; Heeger et al. showed 49% arrhythmia free survival compared to 37% in the control group (p = 0.02). Similar results were achieved in the BELIEF Trial. Nevertheless, there is concern about potential excess stroke risk after electrical isolation of the LAA via catheter ablation, since the procedure creates an akinetic cul-de-sac in communication with the left atrium, which has proven to be highly thrombogenic. Epicardial LAA clip exclusion offers a potential solution to this problem. Using the clip to occlude the LAA, complete electrical isolation of the LAA has been demonstrated, excluding potential AF onset triggers. In the long term, the LAA will regress completely following clip placement. However, there are currently no clear data available demonstrating the additional benefit of LAA clip closure as an addition to thoracoscopic PVI, and more studies are warranted. In rare cases of LAA-driven automatic arrhythmias, stand-alone epicardial clip LAA closure is quite consistently an effective rhythm control strategy and—not infrequently—the best chance for permanent treatment of the arrhythmia.
7 | INDICATIONS FOR EPICARDIAL LAA CLIP CLOSURE

The first line treatment to prevent thromboembolism is of course anticoagulation. In recent years, non-vitamin K oral anticoagulants (NOAC) have proven to be safe and give pharmacological advantages over vitamin K antagonists due to more predictable pharmacokinetics and less need for regular bloodwork and monitoring.47

Current guidelines for AF management suggest considering LAA occlusion as a stroke prevention strategy in patients who have experienced cerebral hemorrhage or other bleeding complications related to long-term anticoagulation therapy and/or patients with AF undergoing cardiac surgery (Class IIb, Level of evidence B).45 These indications are based on randomized clinical trials demonstrating noninferiority of percutaneous devices versus anticoagulation therapy in stroke reduction for patients with AF, creating a basis for LAA closure as an alternative to oral anticoagulation.49-51 However, there is a lack of data providing specific comparisons between percutaneous versus surgical occlusion devices and/or epicardial LAA closure versus NOAC for stroke prevention. The results of the LAACOS III trial, as described previously, could translate to a Class I recommendation for concomitant LAA closure in AF patients with CHA2DS2-VASc ≥2 undergoing cardiac surgery. Accurate detection of underlying cardiomyopathies should be pursued and the benefits of LAA occlusion (thromboembolic prophylaxis and rhythm control), should be balanced against the potential for hemodynamic impairment, especially in patients without persistent arrhythmias. Patients with AF and end-stage renal failure (clearance <15 ml/min) have a contraindication for NOAC but also high risk of bleeding; epicardial LAA occlusion in this specific subset of patients is still undeclared, but might offer a clinical benefit. Whether or not to exclude the LAA should be discussed in a multidisciplinary approach by the AF-Heart Team: a case-by-case analysis of clinical indications, anatomical and morphological considerations. Utilization of risk scores is warranted to provide a patient-tailored approach (guided by CHA2DS2-VASc and HASBLED scores).

In addition to the previously mentioned indications, the 2020 EHRA/EAPCI expert consensus statement on catheter based LAA appendage occlusion summarizes indications for LAA occlusion52 as follows: (1) AF patients eligible for long-term OAC/NOAC who refuse medical treatment despite thorough explanation. (2) AF patients with an absolute contraindication for long-term OAC/NOAC (hemorrhage or side-effects due to VKA/NOAC). (3) AF patients not compliant to medical therapy.

According to the experts, in case of contraindication to antiplatelet therapy, patients may not be eligible for endovascular LAA exclusion, and epicardial clip occlusion should be preferred.53

8 | CONTRAINDICATION FOR EPICARDIAL LAA CLIP CLOSURE

A relative contraindication for LAA clip exclusion derives from the potential negative effects on LV filling properties in patients with severe diastolic dysfunction. In such patients, increased LA compliance via increased volume is key to maintaining a higher reservoir function and thus lower postcapillary pressure. Acute amputation of the LAA, which is the most distensible part of the LA and accounts for 10%–20% of the left atrial volume,54 may cause increased pulmonary pressure and congestion symptoms. Nevertheless, we believe that due to the acute watertight feature of clip exclusion, epicardial LAA clip occlusion may have greater potential for diastolic impairment in selected high-risk patients compared to transcatheter LAA occlusion devices. The latter work more like filters, and endothelialize gradually, leaving a residual distinct endoleak in up to 2/3 of the treated appendages.55

9 | ANTICOAGULATION STRATEGY FOLLOWING LAA OCCLUSION

Selecting appropriate anticoagulation therapy following LAA occlusion remains a challenge. Under current AF anticoagulation guidelines, patients retain a class 1 indication for lifelong therapeutic anticoagulation based on CHA2DS2-VASc risk factors, regardless of whether the LAA is present or not. There are no studies comparing epicardial LAA closure to OAC, so it cannot be considered a replacement treatment. At this time, a contraindication for anticoagulation seems to be the only strong indication for LAA exclusion. In patients with a history of previous uncontrolled life-threatening bleeding, LAA occlusion followed by discontinuation of OAC/NOAC may be a reasonable approach, but requires a careful, tailored approach.

10 | SURGICAL TECHNIQUES

Initially, surgical closure by means of stapling, amputation, ligation and/or direct sew ing provided a high rate of incomplete exclusion, potentially increasing the risk of stroke due to the presence of a residual "pouch" with a thrombogenic effect.3,12 In the past decade, surgical epicardial LAA occlusion by means of a preloaded nitinol clip (Gillinov-Cosgrove LAA clip a.k.a. Atriclip®; AtriCure, Inc.) placed epicardially at the base of the LAA has proven to be a valuable tool with excellent results in terms of safe and durable LAA occlusion.56 Durability and efficacy results were confirmed at 3-years follow-up, in terms of complete occlusion and reduced incidence of stroke and cerebrovascular events in AF patients undergoing concomitant LAA occlusion.57,58 The AtriClip is FDA-approved device for epicardial LAA management. In recent years, several modifications have been made to the original Atriclip to facilitate minimally invasive use (Figure 2).

Ideally, the work up for surgical LAA management includes cardiac CT. This is important to rule out congenital anomalies such as persistent left superior vena cava and understand LAA morphology, while also providing noninvasive screening for possible LAA thrombus. As described above, TOE remains the gold standard to allow safe procedure planning and check for correct LAA clip deployment. TOE should be performed as close as possible to the LAA exclusion procedure, especially when a cardiac CT is not available or feasible (poor renal function, contrast allergy,
impaired transportability). During the procedure, TOE allows for confirmation of freedom from thrombosis—of critical importance, since many patients will not be appropriately anticoagulated, if at all, at this stage—right before deployment, provides endoluminal feedback on a possible residual LAA stump, and helps to rule out possible residual leaks. The latter is less important, as no such findings have been reported since the introduction of the LAA clip.

After general anesthesia and using with selective lung ventilation, the TOE probe is inserted and defibrillation patches are applied. The patient is positioned in dorsal decubitus, with a slight lifting of the left side (we use inflatable balloons), just as one would prepare the right chest for minimally invasive mitral surgery, with the left arm left down.

Three ports are utilized: a camera port aligned with the midsternum (not considering the xyfoid), and two more anterior operating ports: a 5 mm port one intercostal space above and a 10–12 mm port circa 2 intercostal spaces below. (Figure 3) We use a 0° camera through a 10–12 mm viewport. After excluding the right lung from ventilation, aided by CO₂ insufflation at 8–10 cm H₂O, the pericardial sac is opened with endoscissors, cautery or harmonic forceps, parallel to and far from the phrenic pedicle. With normal mediastinal anatomy, retrophrenic pericardial access is preferred, though antephrenic pericardial incision can also provide good exposure, especially when the phrenic pedicle is located posteriorly. A single stay suture on the anterior side of the pericardiotomy may occasionally be used to enhance exposure. The base of the LAA is measured with the AtriClip sizer. A device of appropriate size is then selected and deployed through the inferior 12 mm port. Clip delivery is completely blunt and atraumatic (Figure 4).

Before releasing the device from the deployment tool, electrocardiogram might help rule out exceptionally rare instances of inadvertent coronary compression of the circumflex artery, which might be easily corrected by reopening and repositioning. Following clip placement, TOE is used to confirm complete exclusion, allowing assessment of any residual stump which may require a more proximal repositioning of the device. Although unreported so far with this technology, TOE control can confirm absence of residual leaks across the LAA clip in real-time. Timing of such safety checks is critical; as most LAA clip placements are performed in total absence of anticoagulation, adjustments entailing reopening of the device can only be executed within one minute, as reopening of a LAA clip after longer periods of time might restore flow to an appendage containing thrombus. After LAA clip exclusion, the ports are closed leaving a pleural drainage in the lower port. The procedure lasts around 20 min in experienced hands and the patient is extubated directly post procedure and transferred to a stepdown ward.

11 | SPECIAL CONSIDERATIONS

Due to the complete extracardiac nature of the procedure, no anticoagulation regimen is required. Therefore, LAA clip occlusion is highly suitable for those patients with relative and absolute contraindication to anticoagulant drugs, like those with ongoing bleeding complications.

Since the standard device (Figure 2) has a closed structure, positioning requires it to be placed around the LAA from its distal end,
over the body, to the base of the structure, where it is closed and released. During this process, fresh thrombus within the LAA may be dislodged and embolize. Therefore, LAA thrombosis is a contraindication for LAA epicardial exclusion. Nevertheless, latest generation devices with a V shaped closing mechanism (Figure 2) may provide potential for LAA closure in those patients with refractory LAA thrombosis that is limited to the distal end of the appendage.40

In general, thoracoscopic LAA epicardial exclusion with an Atri-clip device is a very safe and swift procedure.59 To maintain this very low risk threshold, we strongly recommend careful assessment of patients using imaging techniques as previously described (TOE, CT scan, and/or magnetic resonance imaging). From a surgical standpoint, we suggest staying >1 cm from the phrenic nerve, to avoid permanent or transient paralysis of the hemidiaphragm. It is very important to manage the LAA gently, avoiding grabbing the LAA as this tissue can be damaged easily. The device can be positioned very easily by pushing it open on top of the LAA while a-traumatically "caressing" the LAA into the device frame with a peanut device.

Finally, it is very important to understand how this procedure can be also performed in patients with different degree of cardiovascular abnormalities by experienced surgeons. Our experience shows how a complete LAA exclusion was obtained without additional risks in patients with a persistent left superior vena cava (Figure 5) and also in patients with dextrocardia with situs inversus (Figure 6).
CONCLUSIONS

There are several important clinical and theoretical advantages of epicardial LAA clip occlusion, including stroke risk reduction and improved rhythm outcome. Epicardial clip occlusion is reported to be feasible, safe, and very effective, however its role as a stand-alone procedure remains to be established. Currently, isolated epicardial LAA clip closure is reserved for patients with a relative or strict contraindication for anticoagulation and/or antiplatelet therapy, and for those rare case of refractory automatic arrhythmias originating in the LAA. As a concomitant procedure, there is strong evidence that LAA closure can prevent stroke, although further research is needed and current guidelines do not include this recommendation yet.

Understanding of LAA morphology and pathology may help with planning epicardial LAA management.

Adding epicardial LAA clip to the technical armamentarium and openly discussing individual cases within an AF Heart Team is pivotal to developing a personalized approach and identifying the most appropriate LAA treatment for each individual patient.

ACKNOWLEDGMENTS

Open access funding provided by Universita degli Studi di Brescia within the CRUI-CARE Agreement.

ORCID

Fabrizio Rosati http://orcid.org/0000-0002-1475-3156
Gis E. de Maat http://orcid.org/0000-0002-5117-1307

REFERENCES

1. Al-Saady NM, Obel OA, Camm AJ. Left atrial appendage: structure, function, and role in thromboembolism. Heart. 1999;82:547-554.
2. Tilz RR, Rillig A, Thum AM, et al. Catheter ablation of long-standing persistent atrial fibrillation: 5-year outcomes of the hamburg sequential ablation strategy. J Am Coll Cardiol. 2012;60:1921-1929.
3. Badhwar V, Rankin JS, Damiano RJ Jr., et al. The society of thoracic surgeons 2017 clinical practice guidelines for the surgical treatment of atrial fibrillation. Ann Thorac Surg. 2017;103:329-341.
4. Kirchhof P, Benussi S, Kotecha D, et al. 2016 ESC guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur Heart J. 2016;37:2893-2962.
5. Bisleri G, Rosati F, Bontempi L, Curnis A, Muneretto C. Hybrid approach for the treatment of long-standing persistent atrial fibrillation: electrophysiological findings and clinical results. Eur J Cardiothorac Surg. 2013;44:919-923.
6. Rosati F, Muneretto C, Merati E, et al. Epicardial, biatral ablation with integrated uni-bipolar radiofrequency technology in stand-alone persistent atrial fibrillation. Innovations (Philad). 2018;13:114-119.
7. Boersma LV, Castella M, van Boven W, et al. Atrial fibrillation catheter ablation versus surgical ablation treatment (FAST): a 2-center randomized clinical trial. Circulation. 2012;125:23-30.
8. Weimar T, Schena S, Bailey MS, et al. The cox-maze procedure for lone atrial fibrillation: A single-center experience over 2 decades. Circ Arrhythm Electrophysiol. 2012;5:8-14.
9. Healey JS, Crystal E, Lamy A, et al. Left atrial appendage occlusion study (LAAOS): results of a randomized controlled pilot study of left atrial appendage occlusion during coronary bypass surgery in patients at risk for stroke. Am Heart J. 2005;150:288-293.
10. Kanderian AS, Gillinov AM, Pettersson GB, Blackstone E, Klein AL. Success of surgical left atrial appendage closure: assessment by transesophageal echocardiography. J Am Coll Cardiol. 2008;52:924-929.
11. Allawadi G, Gerdts MW, Harvey RL, et al. Exclusion of the left atrial appendage with a novel device: early results of a multicenter trial. J Thorac Cardiovasc Surg. 2011;142:1002-1009.
12. Benussi S, Mazzzone P, Maccabelli G, et al. Thoracoscopic appendage exclusion with an atriclip device as a sole treatment for focal atrial tachycardia. Circulation. 2011;123:1575-1578.
13. Whitlock RP, Belley-Cote EP, Paparella D, et al. LAOOS III Investigators. Left atrial appendage occlusion during cardiac surgery to prevent stroke. N Engl J Med. 2021;384:2081-2091.
14. Sherif HM. The developing pulmonary veins and left atrium: Implications for ablation strategy for atrial fibrillation. Eur J Cardiothorac Surg. 2013;44:792-799.
15. Johnson WD, Ganjoo AK, Stone CD, Srivyas RC, Howard M. The left atrial appendage: our most lethal human attachment! surgical implications. Eur J Cardiothorac Surg. 2000;17:718-722.
16. De Maat GE, Benussi S, Hummel YM, et al. Surgical left atrial appendage exclusion does not impair left atrial contraction function: a pilot study. BioMed Res Int. 2015;2015:318901.
17. Barbier P, Solomon SB, Schiller NB, Glantz SA. Left atrial relaxation and left ventricular systolic function determine left atrial reservoir function. Circulation. 1999;100:427-436.
18. Massoudy P, Belbo S, Raschke P, Zabler S, Becker BF. Influence of intact left atrial appendage on hemodynamic parameters of isolated guinea pig heart. Eur J Med Res. 1998;3:470-474.
19. Ernst G, Stollberger C, Abzieher F, et al. Morphology of the left atrial appendage. Anat Rec. 1995;242:553-561.
20. Murtaza G, Vuddanda V, Akella K, et al. Impact of left atrial appendage occlusion on left atrial function-the LAFIT watchman study. J Interv Card Electrophysiol. 2020;58:163-167.
21. Coisne A, Pilato R, Brigadere F, et al. Percutaneous left atrial appendage closure improves left atrial mechanical function through frank-starling mechanism. Heart Rhythm. 2017;14:710-716.
22. Asmarats L, Bernier M, O’Hara G, et al. Hemodynamic impact of percutaneous left atrial appendage closure in patients with paroxysmal atrial fibrillation. J Interv Card Electrophysiol. 2018;53:151-157.
23. Roy D, Paillard F, Cassidy D, et al. Atrial natriuretic factor during atrial fibrillation and supraventricular tachycardia. J Am Coll Cardiol. 1987;9:509-514.
24. Rodeheffer RJ, Naruse M, Atkinson JB, et al. Molecular forms of atrial natriuretic factor in normal and failing human myocardi. Circulation. 1993;88:364-371.
25. Falcao LM, Pinto F, Ravara L, van Zwieten PA. BNP and ANP as diagnostic and predictive markers in heart failure with left ventricular systolic dysfunction. J Renin Angiotensin Aldosterone Syst. 2004;5:121-129.
26. Kappagoda CT, Linden RJ, Saunders DA. The effect of distending the right and left atrial appendages in the dog. J Physiol. 1972;222:35P-36PP.
27. Maybrook R, Pillarisetti J, Yarlagadda V, et al. Electrolyte and hemodynamic changes following percutaneous left atrial appendage ligation with the LARIAT device. J Interv Card Electrophysiol. 2015;43:245-251.
28. Lakkireddy D, Turagam M, Afzal MR, et al. Left atrial appendage closure and systemic homeostasis: the LAAOHSST study. J Am Coll Cardiol. 2018;71:135-144.
29. Barutz K, Podolec J, Lee RJ, et al. Atrial natriuretic peptide and brain natriuretic peptide changes after epicardial percutaneous left atrial appendage suture ligation using the LARIAT device. J Physiol Pharmacol. 2017;68:117-123.
30. Turagam MK, Vuddanda V, Verberkmoes N, et al. Epicardial left atrial appendage exclusion reduces blood pressure in patients with atrial fibrillation and hypertension. J Am Coll Cardiol. 2018;72:1346-1353.
31. Cox JL, Boineau JP, Schuessler RB, Kater KM, Lappas DG. Five-year experience with the maze procedure for atrial fibrillation. Ann Thorac Surg. 1993;56:823-824.
32. Wang Y, Di Biase L, Horton RP, Nguyen T, Morhanty P, Natale A. Left atrial appendage studied by computed tomography to help planning for appendage closure device placement. J Cardiovasc Electrophysiol. 2010;21:973-982.

33. Di Biase L, Santangeli P, Anselmino M, et al. Does the left atrial appendage morphology correlate with the risk of stroke in patients with atrial fibrillation? Results from a multicenter study. J Am Coll Cardiol. 2012;60:531-538.

34. Korhonen M, Muuronen A, Arponen O, et al. The left atrial appendage is an underrecognized trigger site of atrial fibrillation. Circulation. 1991;84:223-231.

35. Watson T, Shantsila E, Lip GY. Mechanisms of thrombogenesis in atrial fibrillation. Circulation. 2019;139:712.

36. Watson T, Shantsila E, Lip GY. Mechanisms of thrombogenesis in atrial fibrillation. Circulation. 2019;139:712.

37. Blackshear JL, Odell JA. Appendage obliteration to reduce stroke in cardiac surgical patients with atrial fibrillation. Ann Thorac Surg. 1996;61:755-759.

38. Manning WJ, Silverman DI, Keighley CS, Oettgen P, Douglas PS. Transesophageal echocardiographically facilitated early cardioversion from atrial fibrillation using short-term anticoagulation: final results of a prospective 4.5-year study. J Am Coll Cardiol. 1995;25:1354-1361.

39. Cox JL, Ad N, Palazzo T. Impact of the maze procedure on the stroke rate in patients with atrial fibrillation. J Thorac Cardiovasc Surg. 1999;118:833-840.

40. Fleerakkers JA, Hofman FN, Boersma LVA, van Putte BP. Clip the appendage, contain the clot: a small case series. HeartRhythm Case Rep. 2020;6:845-846.

41. Vroemen, M, Luermans JGLM, Meir M, Maesen B. Successful thoracoscopic clipping of a thrombus-containing left atrial appendage. Int J Cardiol Heart Vasc. 2020;26:100460.

42. Hunter RJ, Liu Y, Lu Y, Wang W, Schilling RJ. Left atrial wall stress distribution and its relationship to electrophysiologic remodeling in persistent atrial fibrillation. Circ Arrhythm Electrophysiol. 2012;5:351-360.

43. Di Biase L, Burkhardt JD, Mohanty P, et al. Left atrial appendage: an underrecognized trigger site of atrial fibrillation. Circulation. 2010;122:109-118.

44. Heeger CH, Rillig A, Geisler D, et al. Left atrial appendage isolation in patients not responding to pulmonary vein isolation. Circulation. 2019;139:712-715.

45. Di Biase L, Burkhardt JD, Mohanty P, et al. Left atrial appendage isolation in patients with longstanding persistent AF undergoing catheter ablation: BELIEF trial. J Am Coll Cardiol. 2016;68:1929-1940.

46. Starck CT, Steffel J, Emmert MY, et al. Epicardial left atrial appendage clip occlusion also provides the electrical isolation of the left atrial appendage. Interact Cardiovasc Thorac Surg. 2012;15:416-418.

47. Ruff CT, Giguiano RP, Braunwald E, et al. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: A meta-analysis of randomised trials. Lancet. 2014;383:955-962.

48. Hindricks G, Potpara T, Dagres N, et al. 2020 ESC guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European association of cardio-thoracic surgery (EACTS). Eur Heart J. 2020.

49. Boersma LV, Schmidt B, Betts TR, et al. EWOLUTION investigators. Implant success and safety of left atrial appendage closure with the WATCHMAN device: peri-procedural outcomes from the EWOLUTION registry. Eur Heart J. 2016;37:2465-2474.

50. Winkler S, Miller MA, et al. Epicardial left atrial appendage clipping with the watchman device in patients with a contraindication for oral anticoagulation: the ASAP study (ASA plavix feasibility study with watchman left atrial appendage closure technology). J Am Coll Cardiol. 2013;61:2551-2556.

51. Saw J, Fahmy P, Azzalini L, et al. Early canadian multicenter experience with WATCHMAN for percutaneous left atrial appendage closure. J Cardiovasc Electrophysiol. 2017;28:396-401.

52. Kotecha D, Breithardt G, Camm AJ, et al. Integrating new approaches to atrial fibrillation management: the 6th AFNET/EHRA consensus conference. Europace. 2018;20:395-407.

53. Glikson M, Wolff R, Hindricks G, et al. EHRA/EAPCI expert consensus statement on catheter-based left atrial appendage occlusion—an update. EuroIntervention. 2020;15:1133-1180.

54. Hoit BD, Walsh RA. Regional atrial distensibility. Am J Physiol. 1992;262:H1356-H1360.

55. Sahore A, Della Rocca DG, Anannab A, et al. Clinical implications and management strategies for left atrial appendage leaks. Card Electrophysiol Clin. 2020;12:89-96.

56. Salzberg SP, Plass A, Emmert MY, et al. Left atrial appendage clip occlusion: early clinical results. J Thorac Cardiovasc Surg. 2010;139:1269-1274.

57. Caliskan E, Sahin A, Yilmaz M, et al. Epicardial left atrial appendage AtriClip occlusion reduces the incidence of stroke in patients with atrial fibrillation undergoing cardiac surgery. EuroIntervention. 2018;20:e105-e114.

58. Emmert MY, Puippe G, Baumuler S, et al. Safe, effective and durable epicardial left atrial appendage clip occlusion in patients with atrial fibrillation undergoing cardiac surgery: first long-term results from a prospective device trial. Eur J Cardiothorac Surg. 2014;45:126-131.

59. van Laar C, Verberkmoes NJ, van Es HW, et al. Thoracoscopic left atrial appendage clipping: a multicenter cohort analysis. JACC Clin Electrophysiol. 2018;4:893-901.